阿里健康(00241.HK)推臨床試驗數字化管理平台「碼上放心」
阿里健康(00241.HK)宣布推出「碼上放心」平台,用於新藥研發的臨床試驗藥物編盲與數字化管理,幫助藥企實現臨床試驗藥物全程可追溯。
阿里健康表示,目前中國的臨床試驗用藥還主要靠人工記錄的方法進行管理,難以實現系統化管理、實時監測和全程追溯,而「碼上放心」則為每一盒臨床試驗用藥提供獨一無二的20位追溯碼,全程實現一藥一碼、來源可查、去向可追及溫度可控。
目前中國已有超過98%的藥品生產企業使用「碼上放心」平台,平台服務已延伸到除新藥臨床試驗外的生鮮食品追溯、跨境醫藥電商等多個領域。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.